Concepedia

Peter Schmid

PS

4

Publications

721

Citations

4

H-Index

2023

Active since

Affiliations

Universidad Europea(Current)

Queen Mary University of London

Gilead Sciences (United States)

Vall d'Hebron Hospital Universitari

Universitätsklinikum Erlangen

Peter Schmid is an author at Universidad Europea specializing in breast cancer, cancer therapeutics, and tumor immunity.

Top concepts

Publications per year

2023–2024

4

Publications

4

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

Hope S. Rugo, Aditya Bardia, Frederik Marmé et al. · The Lancet · 2023 · 363 citations · Full text

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Peter Schmid, Javier Cortes, Rebecca Dent et al. · New England Journal of Medicine · 2024 · 310 citations · Full text

Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study

Rebecca Dent, Javier Cortés, Lajos Pusztai et al. · JNCI Journal of the National Cancer Institute · 2024 · 27 citations · Full text

Abstract GS1-11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC)

Hope Rugo, Aditya Bardia, Frederik Marmé et al. · Cancer Research · 2023 · 21 citations

, , +15

Rows per page

1–4 of 4